Carcinoid syndrome: clinical case report of carcinoid tumor: duodenal bulb, lung, renal clear cell carcinoma
DOI:
https://doi.org/10.12775/JEHS.2022.12.03.004Keywords
Bariatric surgery, pregnancy and childbirth, metabolic syndrome, Gastric neuroendocrine (NET) tumor, gastric carcinoid (GC)Abstract
In recent years, bariatric surgery has been the most widespread and, at the same time, the most effective method in the treatment of obesity. It is the most effective therapeutic option for obese patients, but it is associated with a high risk of surgery and late complications related to hormonal disorders, hypoglycemia, osteoporosis, and malabsorption syndrome. In recent years, the number of bariatric surgeries involving independent medical procedures has increased.The patient and the doctors involved in the planned surgery and further treatment should be aware of the possible risks and complications related to pathological obesity and the treatment used. A gastric carcinoid (GC) called gastric neuroendocrine tumor is a rare tumor that originates in gastric enterochromaffin-like cells. More than 75% of GCs are visible changes in endoscopy, the remainder is in the mucosa and is not identified by endoscopy. Therefore, a stomach map with rectal and fundal biopsies is required to confirm its presence. In current NET classifications it is recommended that neuroendocrine tumors (pNET) pancreatic tumors and NET tumors elsewhere be classified as neuroendocrine tumors (NETs)
References
Frühbeck G. Bariatric and metabolic surgery: a shift in eligibility and success criteria. Nature Reviews Endocrinol. 2015;11(8):465–77
Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review.J Amer Med Assoc. 2014:311–74-86.PMID: 24231879.
Hatfield MD, Ashton CM, Bass BL, Shirkey BA. Surgeon-Specific Reports in General Surgery: Establishing Benchmarks for Peer Comparison Within a Single Hospital. J Amer Coll Surg.2015;222:113–121.PMID: 26725243.
Benotti P, Wood CG, Winegar DA, Petrick AT, Still CD, Argyropoulos G, Gerhard GS. Risk factors associated with mortality after Roux-en-Y gastric bypass surgery. Ann Surg.2014;259:123.PMID: 23470583
Flum DR, Dellinger EP. Impact of gastric bypass operation on survival: a population-based analysis. J Am Coll Surg. 2004;199:543–551. PMID: 15454136
Klimstra DS. Pathologic Classification of Neuroendocrine Neoplasms. Hematol Oncol Clin North Am. 2016;30:1–19.
Jensen RT, Norton JA, Oberg K. Neuroendocrine Tumors In Sleisenger and Fordtran’s Gastrointestinal and Liver Diseases, edn tenth Edited by Feldman M, Friedman LS, Brandt LJ. Philadelphia: Elsevier Saunders; 2016. pp. 501–541
Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016;103:153–171.
Al-Efraij K, Aljama MA, Kennecke HF. Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors. Cancer Med. 2015;4:864–870.
Pavel M, Horsch D, Caplin M, et al. Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. J Clin Endocrinol Metab. 2015;100:1511–1519
Howe JR, Cardona K, Fraker DL, et al. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society. Pancreas. 2017;46:715–731. Recent consensus paper on the surgical management of small bowel NETs.
Wolin EM, Jarzab B, Eriksson B, et al. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther. 2015;9:5075–5086.
James AH, Jamison MG et al. Venosus thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. AM J Obstet Gynecol 2006; 194: 1311–1315.
Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017 (in press)
Tsoukalas N, Chatzellis E, Rontogianni D, et al. Pancreatic carcinoids (serotonin-producing pancreatic neuroendocrine neoplasms): Report of 5 cases and review of the literature. Medicine (Baltimore) 2017;96:e6201
Farley HA, Pommier RF. Surgical Treatment of Small Bowel Neuroendocrine Tumors. Hematol Oncol Clin North Am. 2016;30:49–61
Bhattacharyya S, Toumpanakis C, Caplin ME, et al. Analysis of 150 patients with carcinoid syndrome seen in a single year at one institution in the first decade of the twenty-first century. Am J Cardiol. 2008;101:378–381.
Grozinsky-Glasberg S, Grossman AB, Gross DJ. Carcinoid Heart Disease: From Pathophysiology to Treatment—‘Something in the Way It Moves’ Neuroendocrinology. 2015;101:263–273.
Mota JM, Sousa LG, Riechelmann RP. Complications from carcinoid syndrome: review of the current evidence. Ecancermedicalscience. 2016;10:662. Recent review of the complications of carcinoid syndrome.
Tsoukalas N, Chatzellis E, Rontogianni D, et al. Pancreatic carcinoids (serotonin-producing pancreatic neuroendocrine neoplasms): Report of 5 cases and review of the literature. Medicine (Baltimore) 2017;96:e6201
Russo S, Nielen MM, Boon JC, et al. Neuropsychological investigation into the carcinoid syndrome. Psychopharmacology (Berl) 2003;168:324–328
Dobson R, Burgess MI, Valle JW, et al. Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality. Br J Cancer. 2014;111:1703–1709.
Goldman T, Adamson K, Yang E. Resolution of right-sided heart failure symptoms after resection of a primary ovarian carcinoid tumor. Tex Heart Inst J. 2014;41:533–536.
Takada H, Iwatsuki S, Itoh Y, et al. Primary pure carcinoid tumour of the testis: A case report and review of the literature. Arch Ital Urol Androl. 2016;88:245–246
Schieman C, Pasieka JL, McFadden SD, et al. Resolution of chronic diarrhea after resection of a localized pulmonary carcinoid tumor. Ann Thorac Surg. 2010;89:1275–1276
Haq AU, Yook CR, Hiremath V, et al. Carcinoid syndrome in the absence of liver metastasis: a case report and review of literature. Med Ped Oncol. 1992;20:221–223.
Soga J, Yakuwa Y, Osaka M. Carcinoid syndrome: A statistical evaluation of 748 reported cases. J Exp Clin Cancer Res. 1999;18:133–141
Adaway JE, Dobson R, Walsh J, et al. Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement. Ann Clin Biochem. 2016;53:554–560. Study showing accuracy of serum/plasma 5-HIAA determinations.
Toumpanakis C, Caplin ME. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors. Semin Oncol. 2013;40:56–68
Ducreux M. Carcinoid syndrome in neuroendocrine tumors: a prognostic effect? Lancet Oncol. 2017;18:426–428.
Vinik AI, Wolin EM, Liyanage N, et al. Evaluation ofLanreotide Depot/Autogel efficacy and safety as a carcinoid syndrome treatment (elect): A randomized, double-blind placebo-controlled study. Endocr Pract. 2017 In press. Prospective randomized study of effectiveness of Lanreotide autogel in carcinoid syndrome(ELECT study)
Wolin EM, Hu K, Hughes G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study. Cancer Chemother Pharmacol. 2013;72:387–395.
Riechelmann RP, Pereira AA, Rego JF, et al. Refractory carcinoid syndrome: a review of treatment options. Ther Adv Med Oncol. 2017;9:127–137. Paper reviewing new treatments for somatostatin refractory symptoms in carcinoid syndrome patients.
Cazzato RL, Garnon J, Ramamurthy N, et al. 18F-FDOPA PET/CT-Guided Radiofrequency Ablation of Liver Metastases from Neuroendocrine Tumours: Technical Note on a Preliminary Experience. Cardiovasc Intervent Radiol. 2016;39:1315–21.
King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer. 2008;113:921–929
Makary MS, Kapke J, Yildiz V, et al. Conventional versus Drug-Eluting Bead Transarterial Chemoembolization for Neuroendocrine Tumor Liver Metastases. J Vasc Interv Radiol. 2016;27:1298–1304
Maker AV, August C, Maker VK, et al. Hepatectomy After Yttrium-90 (Y90) Radioembolization-Induced Liver Fibrosis. J Gastrointest Surg. 2016;20:869–870
Adamczyk Gruszka O, Lewandowska-Andruszuk I. Ciąża i poród u pacjentki po operacji bariatrycznej i polipektomii z powodu rakowiaka dwunastnicy. Studia Medyczne 2011; 24 (4): 61-65
Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182–188
Cho JH, Ryu JK, Song SY, et al. Prognostic validity of the American Joint Committee on Cancer and the European Neuroendocrine Tumors Staging Classifications for pancreatic neuroendocrine tumors: a retrospective nationwide multicenter study in South Korea. Pancreas. 2016;45:941–946
Kyriakopoulos G, Mavroeidi V, Chatzellis E, Kaltsas GA, Alexandraki KI. Histopathological, immunohistochemical, genetic and molecular markers of neuroendocrine neoplasms. Ann Transl Med. 2018;12
Cummings D, Wong J, Palm R, Hoffe S, Almhanna K, Vignesh S. Epidemiology, diagnosis, staging and multimodal therapy of esophageal and gastric tumors. Cancers. 2021;13:582.
Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion. 1986;35:42–55
Dias AR, Azevedo BC, Alban LBV, et al. Gastric neuroendocrine tumor: review and update. Arq Bras Cir Dig. 2017
Saund MS, Al Natour RH, Sharma AM, Huang Q, Boosalis VA, Gold JS. Tumor size and depth predict rate of lymph node metastasis and utilization of lymph node sampling in surgically managed gastric carcinoids. Ann Surg Oncol. 2011;18:2826–2832
Di Giacinto P, Rota F, Rizza L, et al. Chromogranin A: from laboratory to clinical aspects of patients with neuroendocrine tumors. Int J Endocrinol. 2018:8126087.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Olga Adamczyk-Gruszka, Jakub Gruszka, Grzegorz Świercz, Anna Zwierzyńska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 647
Number of citations: 0
